Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma
Authors:
- 27 December 2012
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 30 (1) , 351
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeAnnals of Oncology, 2009
- Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targetsCritical Reviews in Oncology/Hematology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisoloneAnnals of Oncology, 2008
- Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphomaBritish Journal of Haematology, 2006
- First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphomaLeukemia & Lymphoma, 2006
- Gemcitabine as frontline treatment for cutaneous T‐cell lymphomaCancer, 2005
- Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphomaCancer, 2004
- Treatment of Adult T-cell Leukemia-Lymphoma by CHOP Followed by Therapy with Antinucleosides, Alpha Interferon and Oral EtoposideLeukemia & Lymphoma, 2002
- T-cell Non-Hodgkin's Lymphoma in Adults: Clinicopathological Characteristics, Response to Treatment and Prognostic FactorsLeukemia & Lymphoma, 2002